A detailed history of New Edge Advisors, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 18,015 shares of RNA stock, worth $569,994. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,015
Previous 10,967 64.27%
Holding current value
$569,994
Previous $448,000 84.6%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $262,256 - $339,290
7,048 Added 64.27%
18,015 $827,000
Q2 2024

Aug 15, 2024

BUY
$22.73 - $40.85 $249,279 - $448,001
10,967 New
10,967 $448,000
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $492 - $1,110
49 New
49 $1,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.65B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.